Compare Amphastar Pharmaceuticals Inc (AMPH) vs Capital One Financial Corp. (COF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Capital One Financial Corp. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Capital One Financial Corp. trades at $219.75 (market cap $134.33B). The key difference: Capital One Financial Corp. is far larger — about 155.5× Amphastar Pharmaceuticals Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | COF | |
|---|---|---|
Market Cap | $863.95M | $134.33B |
Sector | Health | Financials |
52-Week High | $30.81 | $257.94 |
52-Week Low | $16.87 | $176.10 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Capital One Financial (COF) trades at $217.76, down 1.02% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81 versus $4.79 expected, driven by strong revenue growth and integration progress with Discover Financial. The stock shows a P/E of 12 and net income margin of 16.96%, reflecting solid valuation and profitability metrics amid ongoing business expansion.
The outlook for COF is positive, supported by earnings momentum, synergy capture from the Discover acquisition, and analyst optimism. Key risks include integration execution, credit loss provisions, and macroeconomic pressures on consumer lending. With 63% of analysts rating it a buy, the stock presents a growth opportunity tempered by sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →
